Abstract
In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-9 |
| Number of pages | 9 |
| Journal | Journal of Clinical Immunology |
| Volume | 20 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2000 |
Keywords
- Autoimmune disease
- Gene-marked autologous stem cells
- Hematopoietic stem cell transplantation
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Fingerprint
Dive into the research topics of 'Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS